Other substances

S2N28

An anti-RBD (SARS-CoV-2 Spike) monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

S2N28 is a human monoclonal antibody neutralizing SARS-CoV-2 in vitro. It was identified in a memory B cell of a convalescent patient. It targets RBD (Thomson et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Spike protein Spike variant Protein factor In vitro Antibody 		Vero E6-TMPRSS2 cells; SARS-CoV-2 Spike-pseudotyped viruses (including WA1/2020 D614G or Omicron) 49.96

The antibody neutralizes Omicron variant of SARS-CoV-2 in vitro. 

 Dec/23/2021
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Spike protein Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody In silico 		Vero E6 cells; Vero E6-hACE2(-TMPRSS2) cells; (VSV) SARS-CoV-2 Spike-pseudotyped virus 41.58

The antibody neutralized Spike (also N439K/K417V)-pseudotyped SARS-CoV-2 in vitro. 

 Mar/04/2021
Export (.csv)